{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:36:17Z","timestamp":1792802177836,"version":"4.5.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.07.003","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:15:05Z","timestamp":1630534505000},"page":"669-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes"],"prefix":"10.1016","volume":"47","author":[{"given":"Hanna","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rdc.2021.07.003_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J\u00a0Autoimmun"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib3","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.rdc.2013.06.001","article-title":"Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"39","author":"Rider","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib5","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.55563\/clinexprheumatol\/4tz6ci","article-title":"Validation of the EULAR\/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients","volume":"39","author":"Sag","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/rheumatology\/keaa429","article-title":"Childhood Myositis Heterogeneity Collaborative Study Group. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America","volume":"60","author":"Mamyrova","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Association of Anti-3-Hydroxy-3-Methylglutaryl-coenzyme a reductase autoantibodies with DRB1\u221707:01 and severe myositis in juvenile myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib9","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.39466","article-title":"Brief report: association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis","volume":"68","author":"Habers","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib10","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib12","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00296-017-3707-4","article-title":"Autoantibodies in children with juvenile dermatomyositis: a single centre experience from North-West India","volume":"37","author":"Hussain","year":"2017","journal-title":"Rheumatol Int"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib13","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00296-016-3494-3","article-title":"Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis","volume":"36","author":"Srivastava","year":"2016","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/14397595.2018.1511025","article-title":"Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan","volume":"29","author":"Iwata","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J\u00a0Pediatr"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib16","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Childhood Myositis Heterogeneity Collaborative Study G. Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib18","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","article-title":"Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis","volume":"68","author":"Deakin","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2012-201736","article-title":"Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort","volume":"72","author":"Fujimoto","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib20","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"10.1016\/j.rdc.2021.07.003_bib23","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib24","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib25","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/rheumatology\/keg403","article-title":"Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis","volume":"42","author":"Ruperto","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.003_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1546-0096-12-31","article-title":"Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research","volume":"12","author":"McCann","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.rdc.2021.07.003_bib27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13063-015-0784-0","article-title":"Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use","volume":"16","author":"McCann","year":"2015","journal-title":"Trials"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/annrheumdis-2017-212141","article-title":"Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research","volume":"77","author":"McCann","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.003_bib29","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/acr.23491","article-title":"Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care","volume":"70","author":"Varnier","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib30","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/rheumatology\/key421","article-title":"Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis","volume":"58","author":"Rosina","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.003_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.200543","article-title":"Pediatric Rheumatology International Trials Organization (PRINTO). Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis","volume":"48","author":"Rosina","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib32","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acr.22142","article-title":"Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"66","author":"Robinson","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.003_bib33","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1136\/annrheumdis-2012-202915","article-title":"Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis","volume":"73","author":"Malattia","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.003_bib34","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/rheumatology\/key144","article-title":"Introduction of a novel magnetic resonance imaging-based scoring system for assessing disease activity in children with juvenile dermatomyositis","volume":"57","author":"Thyoka","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib35","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/ker262","article-title":"Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system","volume":"50","author":"Davis","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/art.23012","article-title":"International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials","volume":"57","author":"Wedderburn","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2013-203396","article-title":"Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease","volume":"74","author":"Varsani","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.23340","article-title":"Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib40","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.10924","article-title":"Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence","volume":"49","author":"Bode","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib41","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/bjd.15596","article-title":"Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool-Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists","volume":"177","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib42","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib43","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib44","first-page":"501","article-title":"Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study","volume":"61","author":"Apaz","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12969-018-0248-7","article-title":"Comparing the importance of quality measurement themes in juvenile idiopathic inflammatory myositis between patients and families and healthcare professionals","volume":"16","author":"Tory","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12969-020-0402-x","article-title":"Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry","volume":"18","author":"Tory","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib47","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.003_bib48","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib49","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/acr.20280","article-title":"The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib50","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/art.40060","volume":"69","author":"Rider","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib51","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","volume":"76","author":"Rider","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib52","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib53","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1542\/peds.2010-3022","article-title":"Familial aggregation of autoimmune disease in juvenile dermatomyositis","volume":"127","author":"Niewold","year":"2011","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib55","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.38137","article-title":"Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders","volume":"65","author":"Miller","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.003_bib56","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1136\/annrheumdis-2015-207762","article-title":"Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis","volume":"75","author":"Lintner","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib57","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/rheumatology\/kex162","article-title":"Environmental factors associated with disease flare in juvenile and adult dermatomyositis","volume":"56","author":"Mamyrova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib58","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.23840","article-title":"Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the childhood arthritis and rheumatology research alliance legacy registry","volume":"71","author":"Neely","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.003_bib59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/acr.22358","article-title":"Risk factors for juvenile dermatomyositis: exposure to tobacco and air pollutants during pregnancy","volume":"66","author":"Orione","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/annrheumdis-2012-201822","article-title":"Whole microvascular unit deletions in dermatomyositis","volume":"72","author":"Gitiaux","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib62","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1038\/s41598-017-09309-8","article-title":"Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis","volume":"7","author":"De Luna","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40478-016-0308-5","article-title":"Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis","volume":"4","author":"Preusse","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib64","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic progenitor cells exhibit Type I interferon-driven proangiogenic properties and molecular signature during juvenile dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib66","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.003_bib67","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of Type I and Type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib68","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/nan.12498","article-title":"Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis","volume":"45","author":"Soponkanaporn","year":"2019","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib69","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.41236","article-title":"Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis","volume":"72","author":"Wienke","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.003_bib70","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3899\/jrheum.181275","article-title":"Endothelial activation markers as disease activity and damage measures in juvenile dermatomyositis","volume":"47","author":"Kishi","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib71","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1002\/art.34606","article-title":"Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib72","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/rheumatology\/keaa270","article-title":"Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk","volume":"60","author":"Wienke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.003_bib73","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","article-title":"CD19(+)CD24(hi)CD38(hi) B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-alpha","volume":"9","author":"Piper","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib74","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3899\/jrheum.120555","article-title":"BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies","volume":"40","author":"Lopez De Padilla","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib75","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","article-title":"Human blood CXCR5(+)CD4(+) T\u00a0cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion","volume":"34","author":"Morita","year":"2011","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib76","doi-asserted-by":"crossref","first-page":"e105353","DOI":"10.1371\/journal.pone.0105353","article-title":"Increased presence of FOXP3+ regulatory T\u00a0cells in inflamed muscle of patients with active juvenile dermatomyositis compared to peripheral blood","volume":"9","author":"Vercoulen","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib77","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3899\/jrheum.160688","article-title":"Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash","volume":"44","author":"Huber","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib80","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Bellutti Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-018-0257-6","article-title":"Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria","volume":"16","author":"Hinze","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib83","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile Dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10019","key":"10.1016\/j.rdc.2021.07.003_bib84","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib85","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1136\/ard.2011.153718","article-title":"Efficacy of intravenous Ig therapy in juvenile dermatomyositis","volume":"70","author":"Lam","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib86","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00296-010-1653-5","article-title":"Mycophenolate mofetil in juvenile dermatomyositis: a case series","volume":"32","author":"Dagher","year":"2012","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib87","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/s10165-012-0647-4","article-title":"Clinical analysis of 50 children with juvenile dermatomyositis","volume":"23","author":"Kishi","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib88","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.40418","article-title":"Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling","volume":"70","author":"Deakin","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib89","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/acr.22198","article-title":"Pilot study of etanercept in patients with refractory juvenile dermatomyositis","volume":"66","author":"Rouster-Stevens","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.rdc.2021.07.003_bib90","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","article-title":"Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis","volume":"149","author":"Liu","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13075-020-02164-5","article-title":"Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients","volume":"22","author":"Campanilho-Marques","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2021.07.003_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/1546-0096-9-S1-O29","article-title":"Effectiveness of anti-TNF-\u03b1 agents in the treatment of refractory juvenile dermatomyositis","author":"Boulter","year":"2011","journal-title":"Pediatr Rheumatol 9, O29"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.003_bib93","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","article-title":"Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis","volume":"47","author":"Riley","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.003_bib94","first-page":"1","article-title":"Abatacept in the Treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.003_bib95","first-page":"406","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis Annals of the Rheumatic Diseases","volume":"80","author":"Kim","year":"2021"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib96","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1093\/brain\/awz005","article-title":"Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis","volume":"142","author":"Papadopoulou","year":"2019","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib97","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib98","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","article-title":"Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review","volume":"60","author":"Yu","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.003_bib99","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2020-218582","article-title":"Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis","volume":"80","author":"Ding","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","article-title":"Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids","volume":"156","author":"Levy","year":"2010","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.003_bib101","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kes232","article-title":"Aerobic fitness after JDM--a long-term follow-up study","volume":"52","author":"Mathiesen","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.003_bib102","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3899\/jrheum.160997","article-title":"Submaximal exercise capacity in juvenile dermatomyositis after longterm disease: the contribution of muscle, lung, and heart involvement","volume":"44","author":"Berntsen","year":"2017","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.003_bib103","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1471-2474-11-270","article-title":"Responsiveness to exercise training in juvenile dermatomyositis: a twin case study","volume":"11","author":"Omori","year":"2010","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib104","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/acr.21684","article-title":"Exercise training in juvenile dermatomyositis","volume":"64","author":"Omori","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.003_bib105","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.nmd.2013.09.002","article-title":"Aerobic training in persons who have recovered from juvenile dermatomyositis","volume":"23","author":"Riisager","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib106","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5606\/ArchRheumatol.2020.7548","article-title":"Assessment of the clinical effects of aquatic-based exercises in the treatment of children with juvenile dermatomyositis: a 2\u00d72 controlled-crossover trial","volume":"35","author":"Samhan","year":"2020","journal-title":"Arch Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.003_bib107","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2474-13-108","article-title":"Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis","volume":"13","author":"Habers","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/acr.20015","article-title":"Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients","volume":"62","author":"Ravelli","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib109","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2019.06.014","article-title":"Long-term outcomes in Juvenile Myositis patients","volume":"50","author":"Tsaltskan","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib110","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/acr.20203","article-title":"Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study","volume":"62","author":"Sanner","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.003_bib111","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keu146","article-title":"Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool","volume":"53","author":"Sanner","year":"2014","journal-title":"Rheumatology (United Kingdom)"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib112","first-page":"782","article-title":"Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients","volume":"28","author":"Mathiesen","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.003_bib113","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/1756-185X.13759","article-title":"Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India","volume":"23","author":"Sharma","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12969-016-0118-0","article-title":"Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study","volume":"14","author":"Okong'o","year":"2016","journal-title":"Pediatr Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.003_bib115","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s10067-014-2675-2","article-title":"Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis","volume":"33","author":"Malek","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.003_bib116","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s10067-014-2747-3","article-title":"Mortality in children with juvenile dermatomyositis: two decades of experience from a single tertiary care centre in North India","volume":"33","author":"Singh","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.003_bib117","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3476(64)80325-5","article-title":"Dermatomyositis","volume":"64","author":"Bitnum","year":"1964","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib118","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.003_bib119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1546-0096-10-34","article-title":"Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience","volume":"10","author":"Patwardhan","year":"2012","journal-title":"Pediatr Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.003_bib120","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/art.27379","article-title":"Association of normal nailfold end row loop numbers with a shorter duration of untreated disease in children with juvenile dermatomyositis","volume":"62","author":"Ostrowski","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21010978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X21010978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:20:23Z","timestamp":1760181623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X21010978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X21010978"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}